Chapel Hill, NC – According to filings with the U.S. Securities and Exchange Commission, Altis Biosystems is raising $3,103,069.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Biron played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Altis Biosystems

Altis’s mission is to develop, manufacture and sell innovative services and research tools to accelerate drug development. Our goal is to reduce the time and cost of drug development with in vitro platforms that more accurately reflect native human biology. Altis Biosystems is a spin-out company from the University of North Carolina at Chapel Hill and based in Durham, North Carolina. The intellectual property behind its stem cell platform was created as part of an NIH Transformative Research Award to develop a microfluidic organ-on-a-chip mimic of the human colon and awarded to Altis’ scientific founders.

To learn more about Altis Biosystems, visit http://altisbiosystems.com/

Contact:
Michael Biron, Chief Executive Officer
516-255-7290
mike@altisbiosystems.com
https://www.linkedin.com/in/michaelbiron/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved